JP5667056B2 - インビボ画像化剤として使用されるイサチン誘導体 - Google Patents

インビボ画像化剤として使用されるイサチン誘導体 Download PDF

Info

Publication number
JP5667056B2
JP5667056B2 JP2011525613A JP2011525613A JP5667056B2 JP 5667056 B2 JP5667056 B2 JP 5667056B2 JP 2011525613 A JP2011525613 A JP 2011525613A JP 2011525613 A JP2011525613 A JP 2011525613A JP 5667056 B2 JP5667056 B2 JP 5667056B2
Authority
JP
Japan
Prior art keywords
compound
isatin
caspase
pyrrolidine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011525613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502014A5 (enExample
JP2012502014A (ja
Inventor
アボアジェ，エリック，オフォリ
スミス，グレアム
グエン，クヮン−デ
アルスタッド，エリック
グレイザー，マシアス，エバーハード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hammersmith Imanet Ltd
Original Assignee
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0816294A external-priority patent/GB0816294D0/en
Priority claimed from GB0818076A external-priority patent/GB0818076D0/en
Application filed by Hammersmith Imanet Ltd filed Critical Hammersmith Imanet Ltd
Publication of JP2012502014A publication Critical patent/JP2012502014A/ja
Publication of JP2012502014A5 publication Critical patent/JP2012502014A5/ja
Application granted granted Critical
Publication of JP5667056B2 publication Critical patent/JP5667056B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011525613A 2008-09-05 2009-09-04 インビボ画像化剤として使用されるイサチン誘導体 Expired - Fee Related JP5667056B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0816294.3 2008-09-05
GB0816294A GB0816294D0 (en) 2008-09-05 2008-09-05 Compounds
GB0818076.2 2008-10-02
GB0818076A GB0818076D0 (en) 2008-10-02 2008-10-02 Compounds
PCT/GB2009/002132 WO2010026388A1 (en) 2008-09-05 2009-09-04 Isatin derivatives for use as in vivo imaging agents

Publications (3)

Publication Number Publication Date
JP2012502014A JP2012502014A (ja) 2012-01-26
JP2012502014A5 JP2012502014A5 (enExample) 2012-10-25
JP5667056B2 true JP5667056B2 (ja) 2015-02-12

Family

ID=41181051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011525613A Expired - Fee Related JP5667056B2 (ja) 2008-09-05 2009-09-04 インビボ画像化剤として使用されるイサチン誘導体

Country Status (10)

Country Link
US (1) US8961930B2 (enExample)
EP (1) EP2367816B1 (enExample)
JP (1) JP5667056B2 (enExample)
KR (1) KR20110066927A (enExample)
CN (1) CN102171208A (enExample)
AU (1) AU2009289062B2 (enExample)
CA (1) CA2735970A1 (enExample)
MX (1) MX2011002498A (enExample)
RU (1) RU2535975C2 (enExample)
WO (1) WO2010026388A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828810A1 (en) 2011-03-01 2012-09-07 Ge Healthcare Limited Radiolabelled octreotate analogues as pet tracers
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
CN103183631B (zh) * 2011-12-28 2016-08-24 天津市国际生物医药联合研究院 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
EP3456718B1 (en) * 2016-05-10 2021-02-17 Fundaçâo Oswaldo Cruz Isatin-derived compounds, use of the compounds for the treatment of aids and hbv infections
CN115171929B (zh) * 2021-04-01 2024-07-16 中核核电运行管理有限公司 重水堆机组给水支管与燃料通道小间隙问题处理的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240648A (en) 1967-08-16 1971-07-28 Wyeth John & Brother Ltd N-substituted isatins
AR016384A1 (es) 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
AU7625500A (en) 1999-09-30 2001-04-30 Smithkline Beecham Corporation Caspases and apoptosis
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
RU2259999C2 (ru) * 2003-08-26 2005-09-10 ООО "Исследовательский институт химического разнообразия" 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
GB0327494D0 (en) 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
US7270799B2 (en) 2004-01-15 2007-09-18 Nst Neurosurvival Technologies Ltd. Perturbed membrane-binding compounds and methods of using the same
US7256198B2 (en) * 2004-02-18 2007-08-14 Wyeth Pyrimidoindolones and methods for using same
GB0428012D0 (en) 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
AU2005324905B2 (en) * 2005-01-17 2012-01-19 Universitaetsklinikum Muenster 5-pyrrolidinylsulfonyl isatin derivatives

Also Published As

Publication number Publication date
AU2009289062A1 (en) 2010-03-11
US20110195024A1 (en) 2011-08-11
EP2367816B1 (en) 2016-11-09
AU2009289062B2 (en) 2015-01-22
RU2011112075A (ru) 2012-10-10
CA2735970A1 (en) 2010-03-11
RU2535975C2 (ru) 2014-12-20
JP2012502014A (ja) 2012-01-26
MX2011002498A (es) 2011-08-04
KR20110066927A (ko) 2011-06-17
EP2367816A1 (en) 2011-09-28
WO2010026388A1 (en) 2010-03-11
CN102171208A (zh) 2011-08-31
US8961930B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
KR101616139B1 (ko) 관류 영상화를 포함하는 용도를 위한 조영제
Smith et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F] fluoroethylazide
JP6254126B2 (ja) 造影剤およびその中間体を合成するための方法および装置
TW201034689A (en) CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
KR101879431B1 (ko) 황화수소 검출용 방사성 프로브
EP3508487B1 (en) Pyrazolo[1,5-a]pyrimidine compound
JP5667056B2 (ja) インビボ画像化剤として使用されるイサチン誘導体
TW201831453A (zh) 四取代烯化合物及其用途
EP4397322A1 (en) Inhibitor of prostate specific membrane antigen and pharmaceutical use thereof
EP3281643A2 (en) Radioactive probe for detecting hydrogen sulfide
DK2699240T3 (en) Acadesinderivater, products, and compositions therefore, their therapeutic uses and processes for their synthesis
KR20170103960A (ko) Pet 영상화제
WO2016174496A1 (en) P-gp radiotracers for imaging as biomarker involved in onset of neurodegenerative diseases
AU2023285721B2 (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
US20090068105A1 (en) Isatin analogues and uses therefor
AU2015200027B2 (en) Contrast agents for applications including perfusion imaging
WO2021123291A1 (en) Oga inhibitor compounds
Mukherjee et al. Nicotinic α4β2 receptor imaging agents
HK40023286A (en) Heteroaryl amides as inhibitors of protein aggregation
HK1151458A (en) Contrast agents for applications including perfusion imaging
HK1151458B (en) Contrast agents for applications including perfusion imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141211

R150 Certificate of patent or registration of utility model

Ref document number: 5667056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees